| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARFIP2 |
| Uniprot No | Q96IU7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-341aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMTDGILG KAATMEIPIH GNGEARQLPE DDGLEQDLQQ VMVSGPNLNE TSIVSGGYGG SGDGLIPTGS GRHPSHSTTP SGPGDEVARG IAGEKFDIVK KWGINTYKCT KQLLSERFGR GSRTVDLELE LQIELLRETK RKYESVLQLG RALTAHLYSL LQTQHALGDA FADLSQKSPE LQEEFGYNAE TQKLLCKNGE TLLGAVNFFV SSINTLVTKT MEDTLMTVKQ YEAARLEYDA YRTDLEELSL GPRDAGTRGR LESAQATFQA HRDKYEKLRG DVAIKLKFLE ENKIKVMHKQ LLLFHNAVSA YFAGNQKQLE QTLQQFNIKL RPPGAEKPSW LEEQ |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARFIP2重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Crystal structure of ARFIP2 in complex with ARL4A*
**作者**：Tarricone C., et al.
**摘要**：该研究解析了重组表达的ARFIP2与ARL4A GTP酶复合物的晶体结构，揭示了ARFIP2通过其BAR结构域结合Arf家族蛋白的分子机制，并探讨了其在膜运输中的潜在作用。
2. **文献名称**：*Regulation of Arfaptin 2 by phosphorylation in neuronal cells*
**作者**：Somanath S., et al.
**摘要**：通过在大肠杆菌中重组表达并纯化人源ARFIP2蛋白，研究发现其磷酸化修饰影响与Arf6的相互作用，进而调控神经细胞突触囊泡运输和神经递质释放。
3. **文献名称**：*Arfaptin 2 modulates α-synuclein aggregation in Parkinson's disease models*
**作者**：Lee H.J., et al.
**摘要**：利用重组ARFIP2蛋白进行体外实验，发现其能够抑制α-突触核蛋白的异常聚集，并通过与Arf1的互作减轻帕金森病模型中的神经元毒性。
(注：以上文献为示例，实际引用时需核对原文信息及数据库准确性。)
**Background of ARFIP2 Recombinant Protein**
ARFIP2 (ADP-ribosylation factor-interacting protein 2) is a regulatory protein involved in intracellular trafficking and cytoskeletal organization. It belongs to the Arf family of small GTPase-interacting proteins and plays a critical role in modulating membrane dynamics by interacting with Arf GTPases, particularly Arf1 and Arf6. These interactions influence vesicle formation, organelle positioning, and receptor trafficking, impacting cellular processes such as endocytosis, secretion, and cell migration.
Structurally, ARFIP2 contains a pleckstrin homology (PH) domain that binds phosphoinositides, enabling membrane association, and an Arf-binding domain that facilitates GTPase interactions. Its activity is regulated by phosphorylation and lipid signaling, linking it to pathways like PI3K/Akt and Rho GTPase signaling. Dysregulation of ARFIP2 has been implicated in pathological conditions, including cancer metastasis, neurodegenerative disorders, and immune dysfunctions, highlighting its therapeutic potential.
Recombinant ARFIP2 protein is engineered for in vitro studies to dissect its molecular mechanisms. Produced using bacterial or mammalian expression systems, it is purified via affinity tags (e.g., His-tag) for functional assays, protein interaction studies, or structural analysis. Researchers utilize this tool to explore ARFIP2’s role in Arf GTPase regulation, its crosstalk with signaling networks, and its contribution to disease pathways. Its applications extend to drug screening, aiming to identify modulators of ARFIP2 activity for therapeutic development.
Overall, ARFIP2 recombinant protein serves as a vital resource for understanding cellular trafficking mechanics and developing targeted interventions for related diseases.
×
